# US 2024/0002937 A1 · Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002937 A1
- Document ID: US20240002937A1
- Status: Published application
- Kind: A1
- Application number: 18/036,439
- Filed: 2021-11-12
- Published: 2024-01-04
- Earliest claimed: 2020-11-12
- Assignees: Ulifetec SAS
- Applicants: Ulifetec SAS
- Inventors: Ulrich Bockelmann; Ismail Cissé
- Web page: https://patentgrep.com/patent/US20240002937A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods of detecting and/or quantifying a RNA, particularly a tRNA, using padlock probes comprising terminal regions complementary to said RNA. The present invention also relates to methods of detecting, diagnosing and/or assessing the clinical severity of an RNA-associated disease.

## Claims

### Claim 1

A padlock probe comprising terminal regions complementary to a tRNA, wherein a terminal region is complementary to a region of the tRNA that is associated with a pathogenic mutation.

### Claim 2 (depends on 1)

The padlock probe according to claim 1, wherein the pathogenic mutation is a pathogenic single-nucleotide variant.

### Claim 3 (depends on 1, 2)

The padlock probe according to claim 1 or claim 2, wherein (i) the tRNA is a leucine(UUR) mt-tRNA and the pathogenic mutation is A3243G or T3271C; or (ii) the tRNA is a lysine mt-tRNA and the pathogenic mutation is A8344G.

### Claim 4

The padlock probe according to any preceding claim, the region of the tRNA that is associated with a pathogenic mutation comprises or consists of:
(i) a fragment of the nucleotide sequence
(SEQ ID NO: 25)
GUUAAGAUGGCAGGGCCCGGUAAUCGCAUAAAACUUAAAACUUUACAGU
CAGAGGUUCAAUUCCUCUUCUUAACACCA,
optionally wherein the fragment comprises nucleotide 14 of SEQ ID NO: 25; or
(ii) a fragment of the nucleotide sequence
(SEQ ID NO: 23)
GUUAAGAUGGCAGAGCCCGGUAAUCGCAUAAAACUUAAAACUUUACAGU
CAGAGGUUCAAUUCCUCUUCUUAACACCA,
optionally wherein the fragment comprises nucleotide 14 of SEQ ID NO: 23.

### Claim 5

The padlock probe according to any preceding claim, wherein a terminal region comprises or consist of the nucleotide sequence TTACCGGGCC (SEQ ID NO: 56) or TTACCGGGCT (SEQ ID NO: 58), or fragments thereof.

### Claim 6

The padlock probe according to any preceding claim, wherein the terminal regions comprise or consist of the nucleotide sequences CTGCCATCTTAAC and TTACCGGGCC (SEQ ID NOs: 55 and 56) or CTGCCATCTTAAC and TTACCGGGCT (SEQ ID NOs: 57 and 58), or fragments thereof.

### Claim 7

The padlock probe according to any preceding claim, wherein the padlock probe comprises or consists of a nucleotide sequence with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to
(SEQ ID NO: 63)
CTGCCATCTTAACTGTAGGGGAGGAGCTGACCACACTTATCATTATCTT
CGCACAGACGTTACCGGGCC
or
(SEQ ID NO: 64)
CTGCCATCTTAACTGGTGAGGTAAAGAACGAAGACTTCTTATCATTATC
TACGAGCGGACGATTACCGGGCT

### Claim 8

The padlock probe according to any preceding claim, wherein the padlock probe comprises or consists of
(SEQ ID NO: 63)
CTGCCATCTTAACTGTAGGGGAGGAGCTGACCACACTTATCATTATCTT
CGCACAGACGTTACCGGGCC
or
(SEQ ID NO: 64)
CTGCCATCTTAACTGGTGAGGTAAAGAACGAAGACTTCTTATCATTATC
TACGAGCGGACGATTACCGGGCT

### Claim 9

The padlock probe according to any preceding claim, wherein the region of the tRNA that is associated with a pathogenic mutation comprises the pathogenic mutation.

### Claim 10

A padlock probe comprising terminal regions complementary to a tRNA, wherein a terminal region is complementary to a region of the tRNA that is associated with a modified nucleotide.

### Claim 11 (depends on 10)

The padlock probe according to claim 10, wherein the modified nucleotide is selected from: N2,N2-dimethyl guanosine (m22G), 5-methylcytosine (m5C), 7-methylguanosine (m7G), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U), 5-methyl uridine (m5U), 1-methylguanosine (m1G), 5-methoxycarbonylmethyluridine (mcm5U), 2-methylthio-N6-threonyl carbamoyladenosine (ms2t6A), 5-taurinomethyluridine (τm5U), 5-taurinomethyl-2-thiouridine (τm5s2U), and 2-thiouridine (s2U).

### Claim 12 (depends on 10, 11)

The padlock probe according to claim 10 or claim 11, wherein the modified nucleotide is 5-taurinomethyluridine (τm5U) or 5-taurinomethyl-2-thiouridine (τm5s2U).

### Claim 13 (depends on 10, 11, 12)

The padlock probe according to any one of claims 10 to 12, wherein the region of the tRNA that is associated with a modified nucleotide comprises an aberrantly modified nucleotide, optionally wherein the aberrant nucleotide modification is the absence of the nucleotide modification.

### Claim 14 (depends on 10, 11, 12, 13)

The padlock probe according to any one of claims 10 to 13, wherein aberrant modification of the modified nucleotide is pathological.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The padlock probe according to any one of claims 10 to 14, wherein (i) the tRNA is a leucine(UUR) mt-tRNA and the modified nucleotide is τm5U or (ii) the tRNA is a lysine mt-tRNA and the modified nucleotide is τm5s2U.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

The padlock probe according to any one of claims 10 to 15, wherein the region of the tRNA that is associated with a modified nucleotide comprises or consists of a fragment of
(SEQ ID NO: 25)
GUUAAGAUGGCAGGGCCCGGUAAUCGCAUAAAACUUAAAACUUUACAGU
CAGAGGUUCAAUUCCUCUUCUUAACACCA
optionally wherein the fragment comprises nucleotide 36 of SEQ ID NO: 25.

### Claim 17

A padlock probe comprising terminal regions complementary to a tRNA comprising a 3′ ligated oligonucleotide, wherein a terminal region is complementary to a region of the tRNA that comprises at least part of the 3′ ligated oligonucleotide.

### Claim 18

The padlock probe according to any preceding claim, wherein the tRNA is a mitochondrial tRNA (mt-tRNA).

### Claim 19

The padlock probe according to any preceding claim, wherein the tRNA is a leucine(UUR) mt-tRNA, a lysine mt-tRNA, a methionine mt-tRNA, a tryptophan mt-tRNA, a aspartate mt-tRNA, an isoleucine mt-tRNA, a glycine mt-tRNA, an arginine mt-tRNA, a histidine mt-tRNA, a serine(AGY) mt-tRNA, a leucine(CUN) mt-tRNA, a threonine mt-tRNA, a phenylalanine mt-tRNA, a valine mt-tRNA, a glutamine mt-tRNA, an alanine mt-tRNA, an asparagine mt-tRNA, a cysteine mt-tRNA, a tyrosine mt-tRNA, a serine(UCN) mt-tRNA, a glutamate mt-tRNA, or a proline mt-tRNA.

### Claim 20

The padlock probe according to any preceding claim, wherein the tRNA is a leucine(UUR) mt-tRNA, a lysine mt-tRNA, a histidine mt-tRNA, a leucine(CUN) mt-tRNA, a phenylalanine mt-tRNA, a valine mt-tRNA, a glutamine mt-tRNA, a serine(UCN) mt-tRNA, or a proline mt-tRNA.

### Claim 21

The padlock probe according to any preceding claim, wherein the tRNA is a leucine(UUR) mt-tRNA or a lysine mt-tRNA, optionally wherein the tRNA is a leucine(UUR) mt-tRNA.

### Claim 22

The padlock probe according to any preceding claim, wherein the region of the tRNA that is associated with a pathogenic mutation, associated with a modified nucleotide or comprises at least part of the 3′ ligated oligonucleotide is 5-30 nucleotides in length, optionally 5-15 nucleotides in length.

### Claim 23

The padlock probe according to any preceding claim, wherein the terminal regions are each 5-30 nucleotides in length, optionally 5-15 nucleotides in length.

### Claim 24

The padlock probe according to any preceding claim, wherein the terminal regions in total are 15-50 nucleotides in length, optionally 20-30 nucleotides in length.

### Claim 25

The padlock probe according to any preceding claim, wherein the terminal regions are complementary to adjacent regions of the RNA.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The padlock probe according to claim any one of claims 1-25, wherein the terminal regions are complementary to non-adjacent regions of the RNA, optionally wherein the non-adjacent regions are separated by 6 or fewer nucleotides, 5 or fewer nucleotides, 4 or fewer nucleotides, 3 or fewer nucleotides, 2 or fewer nucleotides, or one nucleotide.

### Claim 27

The padlock probe according to any preceding claim, wherein the padlock probe is 50-200 nucleotides in length, 50-150 nucleotides in length, 50-100 nucleotides in length, or 70-100 nucleotides in length.

### Claim 28

The padlock probe according to any preceding claim, wherein the padlock probe comprises one or more primer binding sites, optionally wherein the padlock probe comprises a forward primer site and a reverse primer site.

### Claim 29

The padlock probe according to any preceding claim, wherein the padlock probe comprises from 5′ to 3′: a first terminal region; a first primer binding site; a second primer binding site; and a second terminal region; optionally wherein the first primer binding site is a forward primer site and the second primer binding site is a reverse primer binding site, or the first primer binding site is a reverse primer site and the second primer binding site is a forward primer binding site.

### Claim 30 (depends on 28, 29)

The padlock probe according to claim 28 or claim 29, wherein the primer binding sites are 10-30 nucleotides in length.

### Claim 31

The padlock probe according to any preceding claim, wherein the padlock probe comprises a tag or barcode sequence.

### Claim 32

A kit or composition comprising one or more padlock probes according to any preceding claim.

### Claim 33 (depends on 32)

The kit or composition according to claim 32, wherein the one or more padlock probes comprise or consist of:
(i) a first padlock probe comprising terminal regions complementary to a tRNA, wherein a terminal region is complementary to a region of the tRNA that is associated with a pathogenic mutation and the region does not comprise the pathogenic mutation; and
(ii) a second padlock probe comprising terminal regions complementary to said tRNA, wherein a terminal region is complementary to a region of the tRNA that comprises the pathogenic mutation.

### Claim 34 (depends on 33)

The kit or composition according to claim 33, wherein the kit or composition further comprises:
(iii) a third padlock probe comprising terminal regions complementary to a gene encoding said tRNA, wherein a terminal region is complementary to a region of the gene that is associated with a pathogenic mutation and the region does not comprise the pathogenic mutation; and
(iv) a fourth padlock probe comprising terminal regions complementary to the gene encoding said tRNA, wherein a terminal region is complementary to a region of the gene that comprises the pathogenic mutation.

### Claim 35 (depends on 32, 33, 34)

The kit or composition according to any one of claims 32 to 34, wherein the kit or composition further comprises a fifth padlock probe comprising terminal regions complementary to a reference nuclear tRNA, optionally a nuclear methionine tRNA.

### Claim 36 (depends on 32, 33, 34, 35)

The kit or composition according to any one of claims 32 to 35, wherein the kit or composition further comprises a sixth padlock probe comprising terminal regions complementary to a reference mt-tRNA, optionally a methionine mt-tRNA.

### Claim 37 (depends on 32, 33, 34, 35, 36)

The kit or composition according to any one of claims 32 to 36, further comprising one or more primers, optionally one forward primer and one reverse primer.

### Claim 38 (depends on 37)

The kit or composition according to claim 37, wherein the one or more primers are complementary to one or more primer binding sites on the one or more padlock probes.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37, 38)

The kit or composition according to any one of claims 32 to 38, further comprising one or more capture probes.

### Claim 40 (depends on 32, 33, 34, 35, 36, 37, 38, 39)

The kit or composition according to any one of claims 32 to 39, further comprising:
(i) a DNA ligase, optionally a Splint R ligase; and/or
(ii) a DNA ligase buffer, optionally a Splint R ligase buffer.

### Claim 41 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40)

The kit or composition according to any one of claims 32 to 40, further comprising:
(i) an amplification buffer;
(ii) a deoxynucleoside triphosphate (dNTP) mix;
(iii) a DNA polymerase; and/or
(iv) a DNA dye.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method of detecting a tRNA:
(a) providing a sample comprising one or more tRNAs;
(b) hybridising one or more padlock probes defined according to any one of claims 1 to 31 to the one or more tRNAs to obtain one or more hybridised padlock probes;
(c) circularising the one or more hybridised padlock probes to obtain one or more circularised padlock probes;
(d) optionally purifying the one or more circularised padlock probes;
(e) amplifying the one or more circularised padlock probesto obtain amplified padlock probes; and
(f) detecting the amplified padlock probes.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the tRNAs are mitochondrial tRNAs (mt-tRNAs).

### Claim 44 (depends on 42, 43)

The method according to claim 42 or claim 43, wherein the one or more tRNAs are leucine(UUR) mt-tRNAs, lysine mt-tRNAs, methionine mt-TRNAs, tryptophan mt-tRNAs, aspartate mt-tRNAs, isoleucine mt-tRNAs, glycine mt-tRNAs, arginine mt-tRNAs, histidine mt-tRNAs, serine(AGY) mt-tRNAs, leucine(CUN) mt-tRNAs, threonine mt-tRNAs, phenylalanine mt-tRNAs, valine mt-tRNAs, glutamine mt-tRNAs, alanine mt-tRNAs, asparagine mt-tRNAs, cysteine mt-tRNAs, tyrosine mt-tRNAs, serine(UCN) mt-tRNAs, glutamate mt-tRNAs, and/or proline mt-tRNAs.

### Claim 45 (depends on 42, 43, 44)

The method according to any one of claims 42 to 44, wherein the one or more tRNAs are leucine(UUR) mt-tRNAs, lysine mt-tRNAs, histidine mt-tRNAs, leucine(CUN) mt-tRNAs, phenylalanine mt-tRNAs, valine mt-tRNAs, glutamine mt-tRNAs, serine(UCN) mt-tRNAs, or proline mt-tRNAs.

### Claim 46 (depends on 42, 43, 44, 45)

The method according to any one of claims 42 to 45, wherein the one or more tRNAs are leucine(UUR) mt-tRNAs and/or lysine mt-tRNAs, optionally wherein the one or more tRNAs are leucine(UUR) mt-tRNAs.

### Claim 47 (depends on 43, 44, 45, 46)

The method according to any one of claims 43 to 46, wherein the tRNAs comprises a 3′ ligated oligonucleotide and/or the method further comprises a step of ligating an oligonucleotide to the 3′ end of the tRNAs prior to step (b).

### Claim 48 (depends on 42, 43, 44, 45, 46, 47)

The method according to any one of claims 42 to 47, wherein the sample is an RNA sample.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The method according to any one of claims 42 to 48, wherein the sample is obtained or obtainable from urine, muscle and/or blood.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The method according to any one of claims 42 to 49, wherein the method further comprises a step of extracting, purifying and/or isolating the sample from urine, muscle and/or blood.

### Claim 51 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method according to any one of claims 42 to 50, wherein step (c) is performed using a DNA ligase, optionally a Splint R ligase.

### Claim 52 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method according to any one of claims 42 to 51, wherein step (d) is performed by magnetic bead-based purification and/or exonuclease digestion of non-circularised padlock probes.

### Claim 53 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method according to any one of claims 42 to 52, wherein the amplification in step (e) is performed by rolling circle amplification (RCA), optionally hyperbranched RCA (HRCA).

### Claim 54 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method according to any one of claims 42 to 53, wherein step (f) is performed by detecting an increase in fluorescence, optionally the increase in fluorescence is detected in real-time.

### Claim 55 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method according to any one of claims 42 to 54, further comprising a step (g) of quantifying the number of tRNAs.

### Claim 56 (depends on 55)

The method according to claim 55, wherein the number of tRNAs is quantified relative to a reference sample.

### Claim 57

A method of detecting, diagnosing and/or assessing the clinical severity of a tRNA-associated disease comprising:
(a) determining the concentration of wild-type tRNAs (cwt);
(b) determining the concentration of mutant or aberrantly-modified tRNAs (cmut); and
(c) calculating the percentage tRNA mutation load or aberrant-modification load, cmut/(cwt+cmut).

### Claim 58 (depends on 57)

The method according to claim 57, wherein the tRNA-associated disease is a mt-tRNA-associated disease and the tRNAs are mt-tRNAs,

### Claim 59 (depends on 58)

The method according to claim 58, wherein the mt-tRNA-associated disease is mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome or myoclonic epilepsy with ragged red fibers syndrome (MERRF) syndrome, optionally wherein the mt-tRNA-associated disease is MELAS syndrome.

### Claim 60 (depends on 57, 58, 59)

The method according to any one of claims 57 to 59, wherein the concentration of mutant tRNAs is determined, and wherein, optionally: (i) the tRNAs are leucine(UUR) mt-tRNAs and the mutation is m.3243A>G; or (ii) the tRNAs are lysine mt-tRNAs and the mutation is m.8344A>G.

### Claim 61 (depends on 57, 58, 59)

The method according to any one of claims 57 to 59, wherein the concentration of aberrantly-modified tRNAs is determined, and wherein, optionally: (i) the tRNAs are leucine(UUR) mt-tRNAs and the modified nucleotide is τm5U or (ii) the tRNAs are lysine mt-tRNAs and the modified nucleotide is τm5s2U.

### Claim 62 (depends on 57, 58, 59, 60, 61)

The method according to any one of claims 57 to 61, further comprising:
(d) determining the concentration of a reference tRNA (cref); and
(e) calculating the relative quantity of wild-type tRNA molecules, cwt/cref and/or calculating the relative quantity of mutant or aberrantly-modified tRNA molecules, cmut/cref.

### Claim 63 (depends on 62)

The method according to claim 62, wherein the reference tRNA is a nuclear tRNA, optionally a nuclear methionine tRNA, or a mt-tRNA, optionally a methionine mt-tRNA.

### Claim 64 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method according to any one of claims 57 to 63, wherein one or more of cwt, cmut, and cref is determined by a method according to any one of claims 42 to 56.

### Claim 65 (depends on 57, 58, 59, 60, 61, 62, 63, 64)

The method according to any one of claims 57 to 64, further comprising:
(f) determining the concentration of wild-type tRNA genes (c′wt);
(g) determining the concentration of mutant tRNA genes (c′mut); and
(h) calculating the percentage DNA mutation load, c′mut/(c′wt+c′mut).

### Claim 66

Use of a padlock probe for detecting, diagnosing and/or assessing the clinical severity of a tRNA-associated disease.

### Claim 67 (depends on 66)

The use according to claim 66, wherein the tRNA-associated disease is a mt-tRNA-associated disease

### Claim 68 (depends on 67)

The use according to claim 67, wherein the mt-tRNA-associated disease is mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome or myoclonic epilepsy with ragged red fibers syndrome (MERRF) syndrome, optionally wherein the mt-tRNA-associated disease is MELAS syndrome.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 66, 67, 68)

The use according to any one of claims 66-68, wherein the padlock probe is defined according to any one of claims 1 to 31.

### Claim 70

Use of a padlock probe for detecting and/or quantifying tRNA amino-acid charging.
